Mergers and acquisitions (M&A) is a hot topic in the medtech industry. Stryker recently announced a planned acquisition of Wright Medical for approximately $5 billion, which will bolster its orthopedic portfolio and transform it into the upper echelon of leadership within the category. This follows a trend that we’re tracking closely as the industry continues to evolve.
Topics: medtech, medtech marketing, mergers and aquisitions, medtech innovation
This article was originally published in Medtech Insight.
Every medical device company—in and out of the surgical business—and many other tech companies are deep in the war of surgical robotics and digital solutions.
Read MoreTopics: technology, Innovation, medtech, artificial intelligence, AI, robots, medtech innovation, surgery, AI in medtech, surgical technology, da Vinci robot
This post is the second in a multi-part series on how the rules of the road are changing in medtech, and the implications on commercial strategy. Sundeep Karnik contributed to this blog post.
With the speed and impact of innovation increasing rapidly, our institutions have struggled to keep up. For better or worse, rules and regulations have typically lagged behind the innovation frontier, responding only when a crisis or particular incident highlights a new challenge to be managed or risk to be mitigated. This dynamic isn’t specific to healthcare—just think back on all of the questions raised in the last few years with Tesla’s autopilot car crashes to see the parallels. Regardless of industry, for those innovators on the cutting edge, this creates an environment of regulatory uncertainly that is inherently risky for the companies that blaze forward assuming a specific regulatory approach will be adopted by the relevant authorities. The more disruptive the technology, the more likely it is that such an environment will exist.
Read MoreTopics: technology, medtech, medtech marketing, artificial intelligence, FDA, AI, medtech innovation, medtech commercial strategy, AI in medtech, IDx-DR, IDx Technologies
Maria Kliatchko and Indraneel Mukherjee co-wrote this blog post with Arnab Roy. This blog post is the second in a two-part series on how medtech companies can find success with analytics.
Everyone loves the idea of analytics making their lives easier, but in practice medtech companies don’t always realize the broader goals of their analytics programs. Even when analytics initiatives are well planned and executed, they often fail to yield their expected returns due to one factor that often slips under the radar: the human element.
Read MoreTopics: sales reps, AI, data and analytics, next-best actions, data strategy, advanced analytics, sales analytics, medtech innovation, medtech insight, medtech analytics, analytics model, medtech analytics success
With a population of 1.4 billion, China is a market that most medtech companies can’t afford to ignore. However, differences in population types (urban versus rural), the government’s role in healthcare expansion and a multi-tiered distribution system that is undergoing reform make navigating the Chinese market a challenge.
Read MoreTopics: China, medtech, Brian Chapman, medtech innovation, medtech insight, Tim Lee
Mergers and acquisitions (M&A) is a hot topic in the medtech industry. Stryker recently announced a planned acquisition of Wright Medical for approximately $5 billion, which will bolster its orthopedic portfolio and transform it into the upper echelon of leadership within the category. This follows a trend that we’re tracking closely as the industry continues to evolve.
This article was originally published in Medtech Insight.
Every medical device company—in and out of the surgical business—and many other tech companies are deep in the war of surgical robotics and digital solutions.
This post is the second in a multi-part series on how the rules of the road are changing in medtech, and the implications on commercial strategy. Sundeep Karnik contributed to this blog post.
With the speed and impact of innovation increasing rapidly, our institutions have struggled to keep up. For better or worse, rules and regulations have typically lagged behind the innovation frontier, responding only when a crisis or particular incident highlights a new challenge to be managed or risk to be mitigated. This dynamic isn’t specific to healthcare—just think back on all of the questions raised in the last few years with Tesla’s autopilot car crashes to see the parallels. Regardless of industry, for those innovators on the cutting edge, this creates an environment of regulatory uncertainly that is inherently risky for the companies that blaze forward assuming a specific regulatory approach will be adopted by the relevant authorities. The more disruptive the technology, the more likely it is that such an environment will exist.
Maria Kliatchko and Indraneel Mukherjee co-wrote this blog post with Arnab Roy. This blog post is the second in a two-part series on how medtech companies can find success with analytics.
Everyone loves the idea of analytics making their lives easier, but in practice medtech companies don’t always realize the broader goals of their analytics programs. Even when analytics initiatives are well planned and executed, they often fail to yield their expected returns due to one factor that often slips under the radar: the human element.
With a population of 1.4 billion, China is a market that most medtech companies can’t afford to ignore. However, differences in population types (urban versus rural), the government’s role in healthcare expansion and a multi-tiered distribution system that is undergoing reform make navigating the Chinese market a challenge.
View All ZS Offices
